Booth Mark D

Avg. Two Year Performance

No purchase track record
12% Avg. Sale Return
6% Compound
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return----------
Purchase Success Rate----------
Average Sale Return(< 1%)12%14%21%12%
Sale Success Rate4 of 54 of 54 of 52 of 52 of 5

Orexigen Therapeutics, Inc.

Drugs » Drug Manufacturers - Other

Chief Commercial Officer:

Holdings: 3.81K shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--